Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Omega-3 fatty acids for bipolar disorder
Your Article Summary
See Latest ArticlesProtein Kinase C Inhibitors: Rationale for Use and Potential in the Treatment of Bipolar Disorder
CNS Drugs, 06/29/09
Zarate CA et al. - Importantly, the current mainstays in the treatment of mania, lithium (a monovalent cation) and valproate (a small fatty acid) indirectly inhibit PKC. In addition, recent clinical studies with the relatively selective PKC inhibitor tamoxifen add support to the relevance of the PKC target in bipolar disorder.
Related Articles
Stability of symptoms across major depressive episodes in bipolar disorder
Bipolar Disorders, 11/20/09
Relevance Score: 70%
The role of dopamine in bipolar disorder
Bipolar Disorders, 11/19/09
Relevance Score: 70%
Epidemiology and Management of Anxiety in Patients with Bipolar Disorder
CNS Drugs, 10/30/09
Relevance Score: 70%
Bipolar Disorder Patient Care Opportunities: Let's Answer the Call
Annals of Pharmacotherapy, 10/16/09
Relevance Score: 70%
Treatment of Bipolar Disorders and Metabolic Syndrome: Implications for Primary Care
Postgraduate Medicine, 10/15/09
Relevance Score: 70%
Today in Neuropsych Sciences...keeping you current
Receive free subspecialty "5-minute updates" via email
Moving towards ICD-11 and DSM-V: Concept and evolution of psychiatric classification
Indian Journal of Psychiatry, 12/20/09
Factor structure of manic symptoms
Australian and New Zealand Journal of Psychiatry, 12/20/09
Is lithium in a class of its own? A brief profile of its clinical use
Australian and New Zealand Journal of Psychiatry, 12/20/09
Sponsor
Article Search
Sponsor
Sponsor